Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00820846 · ClinicalTrials.gov registry record · Phase 2
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 299
- Enrollment target
NCT00820846 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 299 participants.
The verdict
NCT00820846, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 299 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of and immune response to a two-vaccine regimen in healthy, HIV-uninfected adults who have never received an HIV preventive vaccine before.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL pGA2/JS7 DNA vaccine
- BIOLOGICAL MVA/HIV62 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 299 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00820846
The ClinicalTrials.gov registry entry for NCT00820846 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 299 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00820846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00820846 about?
NCT00820846 is a clinical study titled "Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults". The purpose of this study is to evaluate the safety of and immune response to a two-vaccine regimen in healthy, HIV-uninfected adults who have never received an HIV preventive vaccine before.
What is the current status of trial NCT00820846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 299 participants. The study started on 2009-01. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00820846?
The interventions under investigation include: Placebo (BIOLOGICAL), pGA2/JS7 DNA vaccine (BIOLOGICAL), MVA/HIV62 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00820846?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.